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Abstract
Background: Inhibition of the oncogenic fusion-gene EML4-ALK is a current first-line approach for patients with
stage IV non-small cell lung cancer. While FISH was established as the gold standard for identifying these patients,
there is accumulating evidence that other methods of detection, i.e., immunohistochemistry and next-generation
sequencing (NGS), exist that may be equally successful. However, the concordance of these methods is under
investigation.
Case presentation: Adding to the current literature, we here report a 56 year old female never-smoker with stage
IV lung adenocarcinoma whose biopsy was IHC and FISH inconclusive but positive in NGS. Retroactive profiling of
the resection specimen corroborated fusion reads obtained by NGS, FISH-positivity and showed weak ALK-positivity
by IHC. Consequently, we diagnosed the case as ALK-positive rendering the patient eligible to crizotinib treatment.
Conclusions: With IHC on biopsy material only, this case would have been overlooked withholding effective
therapy.
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Background
Genetic profiling of stage IV lung adenocarcinomas is
state of the art to identify patients who are eligible to
tyrosine kinase inhibitors targeting EGFR, and fused
genes involving ALK, ROS and RET. Following the dis-
covery of the oncogenic EML4-ALK fusion gene by Soda
et al. [1], a series of trial data (phase I-III) published be-
tween 2010 and 2014 demonstrated the efficacy of crizo-
tinib [2–4], a tyrosine kinase inhibitor that was originally
developed to target MET [5] in non-small-cell lung
cancer patients and led to rapid approval of the FDA
and subsequently the EMA. The PROFILE 1014 study
established crizotinib as a first-line therapy yielding a
better progression-free survival than chemotherapy regi-
mens used at that time [4]. The phase I trial by Kwak
et al. [2] used fluorescence in-situ hybridization (FISH)
employing a cut-off of > 15% tumor cells harboring split
signals to determine ALK-positive tumors. A retrospect-
ive analysis of a subset of this cohort showed orthogonal
methods (i.e., RT-PCR and IHC) to correlate with FISH
data to some extent. Consequently, the FDA approved
method for the detection of ALK rearrangements is FISH
while the EMA allows use of any method in Europe that
correctly identifies patients whose tumor harbors ALK fu-
sions. Over the last 5 years there is accumulating data that
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particularly immunohistochemical (IHC) detection of ALK
may be a suitable surrogate marker for rearrangement
events involving ALK [6–9]. However, while concordance
between IHC and FISH is high [9, 10], discordant cases
exist and a number of studies reported ALK- IHC-positive
cases that are negative by FISH [11, 12].
Patient and methods
Written informed consent was obtained, and the case re-
port follows the CARE guidelines [13]. We performed
ALK immunohistochemistry using the D5F3 clone on a
BenchMark XT autostainer with the UltraView DAB de-
tection kit. The antibody is described to be sensitive to
all EM4-ALK variants [6, 10, 14, 15]. FISH analysis and
next generation sequencing were carried out as de-
scribed previously [16]. Briefly, we employed the ALK
dual color break apart probe (Zytovision, Germany) that
detects rearrangements involving the chromosomal re-
gion 2p23.1–p23.2. To this end, the probe labeled with
the green fluorochrome hybridizes proximal to the ALK
gene breakpoint region at 2p23.1–p23.2 and the probe
with the orange fluorochrome hybridizes distal to the
ALK gene breakpoint region at 2p23.2. A normal inter-
phase cell without translocation of this locus shows yel-
low fusions signals whereas separation of signals (a split
signal) indicates translocation/inversion.
Case presentation
We here report the case of a 56 year old Caucasian fe-
male never-smoker, who was initially diagnosed with
clinical stage IIIA adenocarcinoma of the lung in 2014.
The patient underwent surgical resection of the primary
and adjuvant therapy (4 cycles of adjuvant chemotherapy
with cisplatin/vinorelbine). Two years after the resection
of the tumor, the patient developed distant metastatic
disease (Fig. 1a) and was eventually biopsied at the right
iliac bone for pathological evaluation and genetic testing
of druggable targets. We employed combined testing for
fusions and mutations as described previously [16], and
detected fusion of EML4 exon 13 with ALK exon 20,
which is one of the most common fusion variants in
lung adenocarcinomas (variant 1) [17]. Consistent with
this result, we neither detected mutated EGFR or KRAS,
or fusions involving ROS or RET. In parallel, IHC stain-
ing for ALK was applied. While massive parallel sequen-
cing showed 4163 fusion reads indicating expression of
the fusion gene (Fig. 2a) IHC staining was largely nega-
tive except for very few intermingled cells that may show
exceedingly faint ALK expression at high magnification,
which cannot be reliably subtracted from background
signal in routine diagnostics (Fig. 1b, c). Repeated IHC
staining for ALK yielded similar results (data not shown)
and orthogonal FISH analysis showed impaired
hybridization with only very few cells exhibiting probe
signals including splits at low intensity (Fig. 2b). As the
current guidelines require that at least 15% of the tumor
cells show split (or single red) signals [18, 19], FISH data
of the biopsy specimen were inconclusive and thus non-
informative. HE-stained slides suggested crush and ther-
mal artifacts that are known to influence IHC perform-
ance. These divergent findings prompted us to perform
additional molecular profiling of the primary tumor
(Fig. 1d) that was resected two years earlier. In keeping
with the results observed in the biopsy specimen, we de-
tected the very same gene fusion at even higher read
counts (9639 fusion reads; Fig. 2c). In accord with these
genetic data, we detected clear-cut split signals in all can-
cer cells by FISH (Fig. 2d). Corresponding IHC staining of
ALK showed weak ALK expression (Fig. 1e, f ). Based on
the integrated view of these results, we designated this
case as positive for a fusion event involving ALK thus ren-
dering the patient eligible to treatment with crizotinib.
Conclusion
The major trials that lead to the approval of crizotinib
for the treatment of EML4-ALK positive non-small cell
lung cancer patients employed genetic testing by FISH
to identify responders. Consequently, the guidelines for
molecular testing of NSCLC issued by the College of
American Pathologists (CAP), International Association
for the Study of Lung Cancer (ISLAC), and Association for
Molecular Pathology (AMP) in 2013 [19], recommend dual
color FISH for the detection of fusion events that predict re-
sponse towards therapy, and IHC as a putative screening
method for cases that require FISH testing. Over the last
3 years, a number of studies have reported a high concord-
ance of FISH and IHC data. However, concordance results
did not reach 100% and a large study of 3244 cases identified
a substantial number of cases that were either FISH-
positive/IHC-negative or FISH-negative/IHC-positive [20].
The authors of this study conclude that using either test
alone would have failed to detect about 25% of ALK-positive
cases. A recent study by Pekar-Zlotin et al. [21] concluded
that FISH-based testing may miss a significant number of
patients who are eligible to ALK inhibition and observed a
sensitivity and specificity of 42.9% and 97.7% for FISH and
100 and 97.7% for IHC compared to an NGS-based ap-
proach that served as a gold standard for ambiguous cases.
Based on their experience with 51 patients they suggested
that NGS should be applied in cases with inconclusive IHC
staining. Costs for an NGS-based approach are currently
higher than for a single FISH analysis if one compares both
methodologies on the basis of a single analysis (e.g., ALK
testing). However, the NGS methodology allows simultan-
eous upfront detection of clinically relevant pointmutations,
amplifications, deletions and gene fusions in a one-stop shop
which is highly efficient and tissue sparing [16]. The latter is
a crucial point when it comes to small biopsies where tumor
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cellularity may be low. NGS also provides data on the fusion
partners which may become relevant in the future. With
dropping costs, advantageous NGS-based assays will most
likely replace combinatory approaches of e.g., Sanger
sequencing (for detection of mutant EGFR) and FISH ana-
lysis, which are still the mainstay of molecular diagnostics
and which are also used by us as robust and orthogonal
methods.
Fig. 1 HE-staining and ALK-IHC of the NSCLC (scale bar indicates magnification). a HE-stained biopsy specimen, b Biopsy specimen: Overview of
ALK-IHC staining, c Biopsy specimen: High power view of ALK-IHC staining. Insert shows a positive case with strong staining serving as internal
control., d HE-stained surgical specimen, e Surgical specimen: Overview of ALK-IHC staining, f Surgical specimen: High power view of ALK-IHC
staining. Insert shows a positive case with strong staining serving as internal control
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Here, we show a case where ALK-IHC was negative in
the biopsy material, except for very few intermingled
cells exhibiting extremely faint positivity that cannot be
reliably discriminated from background signals. Simi-
larly, FISH showed poor hybridization performance and
results were non-informative. Concomitant targeted
deep sequencing, however, that was implemented at our
institution [16], showed the classic variant 1 fusion be-
tween EML4 and ALK affecting exons 13 and exon 20,
respectively. These divergent results prompted us to
profile the surgical resection specimen by NGS where
we observed the very same fusion event and, in accord
with this finding, detected clear-cut split signals in the
FISH analysis as well as weak but positive ALK immu-
nostaining. Weak IHC signals in FISH-positive ALK
cases are well known and have been reported in the lit-
erature [22–24]. While the underlying cause is unclear,
antibody avidity may account for some of the cases. As all
formalin and paraffin embedded specimens at our institu-
tion are processed according to standard protocols and
standard operating procedures that are continuously
monitored by quality management, a systematic error is
unlikely. We did not observe any evidence for genetic het-
erogeneity in the surgical specimen, i.e., the ALK fusion
event was present in all tumor cells which is consistent
with the concept of mutual exclusivity with other main
drivers, e.g., mutant EGFR, and the notion that ALK fu-
sion are truncal mutations. As hybridization performance
for FISH was poor in the biopsy specimen and targeted
RNA sequencing does not provide data on a single cell
level, we cannot exclude genetic heterogeneity in the bi-
opsy but it appears unlikely for the reasons mentioned
above. In theory, epigenetic silencing could be causal for
the absent protein expression in the biopsy specimen.
However, our targeted RNA-seq data clearly demonstrate
transcription of the fusion sequence (i.e. no gene silencing)
and is also in line with the notion that downregulation of
the main driver would be disadvantageous for tumor
growth and spread. In summary, taken the data of both
specimens into account, we diagnosed an ALK-positive
lung adenocarcinoma rendering the patient eligible to
crizotinib.
Fig. 2 Genetic analysis of the biopsy and surgical specimen. a Reads of the E13-A20 EML4-ALK fusion transcript in the biopsy specimen. b Reads
of the E13-A20 EML4-ALK fusion transcript in the surgical specimen. c FISH analysis of the biopsy specimen. Asterisk marks fused signal, arrow points to
splits signal. d FISH analysis of the surgical specimen. Arrows indicate split signals. Both FISH pictures were taken at 100× magnification using oil
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While we cannot fully explain the negative FISH and
IHC results on the biopsy specimen, conventional morph-
ology of the small iliac biopsy suggests that crush or ther-
mal artifacts introduced by cauterization and surgical
instruments likely account for the drop out. As our quality
controlled NGS approach yielded clear results for both the
biopsy as well as for the surgical specimen, this case illus-
trates that NGS-based detection of ALK fusions is particu-
larly advisable in cases where FISH and IHC results are
inconclusive or tissue artifacts are suspected to avoid false
negative results that may withhold effective therapy. This
being said, further studies are warranted to comprehen-
sively investigate the diagnostic utility and power of the
three different methods in specific clinical settings.
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